Biocryst Pharmaceuticals (BCRX) Depreciation & Amortization (CF) (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Depreciation & Amortization (CF) of $461000.0 for Q1 2026, up 17.01% on a QoQ basis from $394000.0 in Q4 2025, and up 39.27% year-over-year from $331000.0 in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $461000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 39.27% year-over-year to $461000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 19.51% YoY) and the FY2025 annual result came in at $1.4 million, up 11.48% from the prior year.
- Depreciation & Amortization (CF) was $461000.0 for Q1 2026 at Biocryst Pharmaceuticals, up from $394000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $461000.0 in Q1 2026 and bottomed at $306000.0 in Q1 2024.
- A 5-year average of $364000.0 and a median of $335000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 131.58% — and 2024, when it declined 26.95%.
- Biocryst Pharmaceuticals' Depreciation & Amortization (CF) stood at $396000.0 in 2022, then rose by 6.82% to $423000.0 in 2023, then dropped by 26.95% to $309000.0 in 2024, then grew by 27.51% to $394000.0 in 2025, then rose by 17.01% to $461000.0 in 2026.
- Business Quant data shows BCRX's Depreciation & Amortization (CF) at $461000.0 in Q1 2026, $394000.0 in Q4 2025, and $335000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | 461,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 461,000.00 |
| Mar 31, 2026 | 461,000.00 |
| Dec 31, 2025 | 394,000.00 |
| Dec 31, 2025 | 394,000.00 |
| Sep 30, 2025 | 335,000.00 |
| Sep 30, 2025 | 335,000.00 |
| Jun 30, 2025 | 329,000.00 |
| Jun 30, 2025 | 329,000.00 |
| Mar 31, 2025 | 331,000.00 |
| Mar 31, 2025 | 331,000.00 |
| Dec 31, 2024 | 309,000.00 |
| Dec 31, 2024 | 309,000.00 |
| Sep 30, 2024 | 311,000.00 |
| Sep 30, 2024 | 311,000.00 |
| Jun 30, 2024 | 320,000.00 |
| Jun 30, 2024 | 320,000.00 |
| Mar 31, 2024 | 306,000.00 |
| Mar 31, 2024 | 306,000.00 |
| Dec 31, 2023 | 423,000.00 |
| Dec 31, 2023 | 423,000.00 |